# A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

> **NCT07180355** · PHASE1 · RECRUITING · sponsor: **Solid Biosciences Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Friedreich's Ataxia (FA)

## Interventions

- **DRUG:** SGT-212

## Key facts

- **NCT ID:** NCT07180355
- **Lead sponsor:** Solid Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2028-03-21
- **Final completion:** 2032-02-29
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07180355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07180355, "A Study of SGT-212 Gene Therapy in Friedreich's Ataxia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07180355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*